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ABSTRACT  
Previous reports suggest that community-acquired pneumonia (CAP) is associated with an enhanced 
risk of myocardial infarction (MI) and that enhanced platelet activation may play a role.  
Aims of this study were to investigate if urinary excretion of 11-dehydro-thromboxane (Tx) B2, a 
reliable marker of platelet activation in vivo, was elevated in CAP and whether glucocorticoid 
administration reduced platelet activation. 
Three-hundred patients hospitalized for CAP were recruited and followed-up until discharge. Within 
the first 2 days from admission, urinary 11-dehydro-TxB2 and serum levels of methylprednisolone 
and betamethasone were measured.  11-dehydro-TxB2 was also measured in a control group of 150 
outpatients, matched for age, sex, and comorbidities. Finally, in-vitro studies were performed to 
assess if glucocorticoids affected platelet activation, at the same range of concentration found in 
the peripheral circulation of CAP patients treated with glucocorticoids.  
Compared to controls, CAP patients showed significantly higher levels of 11-dehydro-TxB2 (110 [69-
151] vs. 163 [130-225] pg/mg creatinine; p<0.001). During the in-hospital stay, 31 patients 
experienced MI (10%). A COX regression analysis showed that 11-dehydro-TxB2 independently 
predicted MI (p=0.005). CAP patients treated with glucocorticoids showed significantly lower levels 
of 11-dehydro-TxB2 compared to untreated ones (147 [120-201] vs. 176 [143-250] pg/mg creatinine; 
p<0.001). 
In vitro, glucocorticoids-treated platelets showed a dose-dependent decrease of ADP-induced 
platelet aggregation, TxB2 production, cPLA2 phosphorylation and arachidonic acid release from the 
platelet membrane.  
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In conclusion, platelet TxB2 is overproduced in CAP patients and may be implicated in MI occurrence. 
Glucocorticoids reduce platelet release of TxB2 in vitro and urinary excretion of 11-dehydro-TxB2 in 
vivo and may be a novel tool to decrease platelet activation in this setting. 
 
ABBREVIATIONS: 
 
AA:   arachidonic acid 
CAF:   chronic (persistent or permanent) atrial fibrillation 
CAP:    Community-acquired pneumonia  
CHD:   coronary heart disease 
COPD:   chronic obstructive pulmonary disease 
CVE:   cardiovascular event 
HF:   heart failure 
HS:   healthy subjects 
MI:   myocardial infarction 
PAD:   peripheral arterial disease 
PAF:   paroxysmal atrial fibrillation 
PRP:   platelet-rich plasma 
PSI:   pneumonia severity index 
T2DM:   type 2 diabetes mellitus 
Tx:   Thromboxane 
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1. INTRODUCTION  
Community-acquired pneumonia (CAP) is one of the most common causes of hospitalization in 
medical wards and represents a serious social issue. In fact, the incidence of CAP steadily increases 
with age and is associated with a higher rate of morbidity and mortality, particularly in the elderly 
[1]. Among the reasons for the increased risk of morbidity and mortality, thrombotic complications 
occurring in the coronary and cerebral districts seem to play an important role. In a recent 
multicenter study conducted in 1,182 patients hospitalized for CAP, 32.2% experienced 
cardiovascular disease including heart failure (HF), myocardial infarction (MI), atrial fibrillation (AF) 
and stroke during the in-hospital stay [2]. The occurrence of such complications has a relevant 
clinical impact since CAP patients experiencing cardiovascular events (CVEs) during hospitalization 
are at higher risk of mortality and cardiovascular recurrences in short- and long-term follow-up [2, 
3]. Among the factors influencing the occurrence of in-hospital CVEs, the severity of pneumonia has 
a prominent role as indicated by the independent association between pneumonia severity index 
(PSI) score and cardiovascular events [2]. Other factors contributing to in-hospital CVEs could 
include platelet activation, since ex-vivo markers of platelet activation, such as soluble CD40L, 
soluble P-selectin and serum thromboxane (Tx) B2, are elevated during the acute phase of the 
disease and independently predict MI [4]. However, neither these soluble serum markers nor serum 
TxB2 adequately reflect platelet activation in vivo [5], thus further study is necessary to assess if 
platelets are really overactivated in CAP patients. Furthermore, CAP patients treated with aspirin 
did not display complete COX1 inhibition [4], suggesting that other pathways of platelet activation 
could be targeted to prevent platelet activation in this clinical setting [6-8]. 
Previous studies investigated whether glucocorticoids could improve clinical outcomes such as 
mortality in CAP patients, but the results were equivocal [9, 10].  Experiments in vitro and in vivo 
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demonstrated that glucocorticoids inhibit platelet aggregation and platelet-related arterial 
thrombosis [11-14]; conversely, interventional studies with variable glucocorticoid doses showed 
no effect on ex-vivo platelet aggregation and urinary excretion of 11-dehydro-TxB2 [15-17], a reliable 
marker of platelet activation in vivo [18].  To further explore this issue, we  investigated 1) if platelet 
activation assessed by urinary excretion of 11-dehydro-TxB2 is elevated in a large population 
affected by CAP compared to controls, matched for demographic and clinical characteristics, 2) if 
elevated levels of urinary excretion of 11-dehydro-TxB2 are associated with MI risk in this cohort of 
CAP patients, 3) if glucocorticoid administration reduces platelet activation of CAP patients in vivo 
and 4) if glucocorticoids affect platelet activation  in vitro, at the same range of concentration found 
in the peripheral circulation of CAP patients treated with glucocorticoids.  
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2. MATERIALS AND METHODS 
2.1. Study Population 
This cohort study recruited patients from January 2012 to July 2017 at three medical centers 
of the University-Hospital Policlinico Umberto I, Rome, Italy (Department of Internal Medicine and 
Medical Specialties, Department of Clinical Medicine, Department of Public Health and Infectious 
Diseases). 
After they gave written informed consent, we enrolled 300 consecutive patients who fulfilled 
the following criteria in the study: (1) age ≥18 years; (2) clinical presentation of an acute illness 
with at least two or more of the following signs or symptoms of CAP: presence of rales, rhonchi, 
bronchial breath sounds, dullness, increased fremitus and egophony, fever (>38.0˚C), tachycardia, 
chills, dyspnea, coughing (productive or unproductive cough), chest pain; and (3) presence of new 
consolidation(s) on chest X-ray. Pneumonia was considered as CAP if it was diagnosed upon 
hospitalization and the patient had not been discharged from an acute care facility within 14 days 
preceding the clinical presentation [2]. 
Patients were excluded from the study if any of the following criteria applied: radiographic 
evidence of pre-existing infiltrates; immunosuppression (HIV infection, chemotherapy, high dose 
of immunosuppressive agents to prevent the rejection of transplanted organs and tissues or to 
treat autoimmune diseases); presence of malignancy; pregnancy or breastfeeding; documented 
severe allergy to antibiotics; healthcare-associated pneumonia [19]. 
One-hundred and fifty controls were selected among outpatients referring to the Day Service 
of Internal Medicine and to the center for monitoring and management of antithrombotic 
therapies of the Department of Internal Medicine and Medical Specialties, Sapienza University 
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Hospital. They were matched for age, sex, smoking habit, and comorbidities, including 
hypertension, diabetes, CHD, HF, dyslipidemia and chronic renal failure.  
The present study was conducted according to the principles stated in the Declaration of 
Helsinki. The institutional review boards at each Institution approved this study, which was 
registered at ClinicalTrials.gov (Identifier: NCT01773863). 
 
2.2 Baseline assessment  
Data on demographic characteristics, comorbidities and concomitant therapy were collected. 
The severity of illness at presentation was quantified by the Pneumonia Severity Index (PSI), a 
validated prediction score for 30-day mortality [20].  
The PSI score is comprised of several variables: age, gender, co-morbid illnesses, vital sign 
abnormalities, plus laboratory, blood gas, and radiographic parameters.  The score was 
calculated as presented in the study by Fine et al. [20] and divided in five classes. Patients in the 
first three classes are considered at low risk, patients in the fourth class at moderate risk and 
patients in the fifth class at high risk. 
Pre-existence of T2DM, hypertension, dyslipidemia, history of CHD, COPD, PAD, HF, and AF 
were defined as previously described [21-25]. Baseline treatments were defined according to the 
patients’ pharmacological history.  
Immediately after diagnosis of CAP, routine blood laboratory tests including serum high-
sensitivity cardiac troponin T (hs-cTnT), a 12-lead electrocardiography and arterial blood gas test 
were performed.  
 
2.3 Assessment of myocardial infarction during the in-hospital stay. 
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The occurrence of an MI was diagnosed according to the “Third Universal Definition of 
Myocardial Infarction” [26], ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI) were 
defined as previously reported [26] and were confirmed by cardiologists. 
 
2.4 Urinary TxB2 assay 
Urinary 11-dehydro TxB2 was analyzed by ELISA commercial kit (Cayman, USA). The absorbance 
was measured with a microplate reader at 405 nm and expressed as pg/mg creatinine. Intra-assay 
and inter-assay coefficients of variation were 3.6% and 7.6%.  
 
2.5 HPLC determination of Methylprednisolone and Betamethasone in serum 
Serum sample was collected in BD Vacutainer (Franklin Lakes, New Jersey, USA) without 
anticoagulant (code 367615) by centrifugation at 300g for 10 min at room temperature. The 
supernatant serum was divided into aliquots and stored at −80°C for analyses. Stock solutions of 
methylprednisolone and betamethasone were prepared at a concentration of 1 mg/ml in methanol 
and diluted to 100 µg/ml in methanol for working stock solution. A stock solution of internal 
standard (IS, 17α-Hydroxyprogesterone; Sigma Aldrich, Saint Luis, USA) in methanol was prepared 
and diluted to 150 µg/ml. Standard solutions of methylprednisolone and betamethasone were 
prepared in the mobile phase and IS was spiked to achieve a constant concentration of 5 µg/ml.  
500 µl of 5% acetic acid solution containing IS and 5 ml of hexane were added to 500 µl of serum 
into a test tube and centrifuged for 5 minutes at 1400g. After extraction with ethyl acetate, samples 
were evaporated to dryness. The residue was dissolved in 500 µl of mobile phase and 25 µl were 
injected into the column and analyzed using an Agilent 1200 Infinity series high-performance liquid 
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chromatography system equipped with an Eclipse Plus C18 column (4.6 x100 mm). The mobile phase 
was prepared by mixing acetonitrile-water-glacial acetic acid (35:62:2% v/v) with a flow rate of 1.2 
ml/min and peaks were analyzed at 254 nm. 
 
2.6 In vitro study 
2.6.1 Platelet Aggregation  
Venous blood was drawn in trisodium citrate (3.8%, 1/10 (v: v)) from healthy subjects (HS, n=5) 
who had fasted for at least 12 hours. To obtain platelet-rich plasma (PRP), blood was centrifuged 
for 15 min at 180 g at room temperature and the supernatant PRP was separated (2 x 105 platelets/ 
μl). To avoid leukocyte contamination, only the top 75% of the PRP was collected. Within thirty 
minutes after venipuncture, PRP samples (250 μl) were pre-incubated (20 minutes at 37°C) with 
scalar concentration (150-300-600 ng/ml) of methylprednisolone (Sigma Aldrich, Saint Luis, USA) or 
betamethasone (Sigma Aldrich, Saint Luis, USA) or equal volumes of DMSO (5%). After incubation, 
samples were stimulated with collagen (2 μg/ml; Mascia Brunelli) or adenosine diphosphate (ADP, 
10 M; Sigma Aldrich, Saint Luis, USA) for 10 minutes at 37°C. Platelet aggregation was performed 
on a Bio/Data 8-channel platelet aggregometer (PAP-8E BioData) according to the method of Born 
[27]. After stimulation with agonists, samples were centrifuged for 3 minutes at 3000 rpm. 
Supernatants were stored at -80°C for analysis of TxB2 and pellets were stored at -80°C for analysis 
of cPLA2 phosphorylation and arachidonic acid production.  
 
2.6.2 Western blot analysis of cPLA2 protein phosphorylation 
Platelet pellets were suspended in a 2X Lysis buffer (5 mM EDTA, 0.15 mol NaCl, 0.1 mol Tris pH 
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8.0, 1% Triton and 10 µg/ml of protease and phosphatase inhibitors cocktail). The protein 
concentration of each lysate was determined by Bradford assay.  Equal amounts of protein (30 
μg/lane) were solubilized in a 2X Leammli sample buffer containing 20% of 2-mercaptoethanol and 
were electrophoretically separated on a 10% SDS-polyacrylamide gel and then electrotransferred to 
nitrocellulose membranes. After blocking with Bovine Serum Albumin (BSA) 5% (Sigma Aldrich, Saint 
Luis, USA) the membranes were incubated overnight at 4°C with a polyclonal anti-p-cPLA2 antibody 
or a polyclonal anti-cPLA2 antibody (both Santa Cruz Biotechnology). Subsequently, the membranes 
were incubated with secondary antibody (Santa Cruz Biotechnology, 1:5000) and then the immune 
complexes were detected by enhanced chemiluminescence substrate. Densitometric analysis of the 
bands was performed using Image J software.  
 
2.6.3 Platelet TxB2 assay 
Platelet TxA2 generation was analyzed as previously described [28] by evaluating its stable 
metabolite TxB2 by ELISA commercial kit (Cusabio, USA) and expressed as pg/ml x108 cells. Intra- and 
inter-assay coefficients of variation for TxB2 were 4.0% and 3.6%, respectively.  
 
2.6.4 Platelet arachidonic acid assay 
Arachidonic acid was analyzed in platelets by gas chromatography as previously described [29, 
30]. Briefly, Arachidonic acid was processed for direct transesterification with acetyl chloride and 
evaluated using mixtures of authentic methylated Fatty Acid standards and a control plasma pool 
as previously described [31]. Analyses were performed on an Agilent 7820A Plus Gas 
Chromatograph (Agilent Technologies) equipped with a G4513A automatic liquid sampler and a 
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flame-ionization detector (GC-FID). Separation was carried out on a 100-m capillary column 
(Supelco, SP-2560 100 m 3 0.25 mm inner diameter, 0.20 mm thickness; Sigma Aldrich, Milan, Italy). 
 
2.7 Statistical analysis 
2.7.1 Sample size  
The minimum sample size was computed considering a relevant difference in urinary 11-
dehydro-TxB2 levels to be detected between groups |δ|≥20 pg/mg/creatinine, (ii) SD of the paired 
differences SD=30 pg/mg creatinine (iii) a type-I error probability α=0.05 and power 1-β=0.90. This 
resulted in a minimum of 48 patients per group.  
 
2.7.2 Statistical methods  
All continuous variables were tested for normality with the Shapiro-Wilk test. Variables with 
normal distribution were expressed as means and standard deviations (SD) and tested for 
differences using a t-test. Appropriate nonparametric tests were employed for all the other 
variables. Non-parametric variables were expressed as median and interquartile range (IQR). 
Categorical variables were expressed as percentages and analyzed by chi-squared test. 
Cox proportional hazards analysis was used to calculate the adjusted relative hazards of MI by 
each clinical variable.  
In addition to urinary 11-dehydro TxB2, possible independent variables considered were age, 
sex, body mass index (BMI), PSI score, smoking habit, history of CHD and stroke, dyslipidemia, T2DM, 
hypertension, HF, chronic kidney disease, COPD, PAD, PAF, and CAF.  Stochastic level of entry into 
the model was set at a p-value=0.10, and interaction terms were explored for all the variables in the 
final model. For multivariate models, model selection was performed using forward stepwise 
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regression. To avoid collinearity issues, age did not enter the multivariate model, as it is a 
fundamental component of the PSI score [20]. 
Nonparametric tests were employed in the analysis of the in vitro study.  As an overall non‐
parametric ANOVA, the Friedman test for the analysis of intragroup variations was used. In cases of 
significance, we compared pair related samples using the Wilcoxon test.  
Only p values <0.05 were regarded as statistically significant. All tests were 2-tailed and analyses 
were performed using computer software packages (IBM SPSS Statistics 24.0; R version 2.15.2, R 
Development Core Team, Vienna, Austria). 
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3. RESULTS 
3.1 Urinary 11-dehydro-TxB2 in CAP patients and controls. 
Clinical characteristics of CAP patients and controls are reported in table 1.  
Three-hundred patients hospitalized for CAP (201 males; 99 females; age: 74.3 ± 14.1 years) 
were recruited. Most of the patients had arterial hypertension (74%). A history of coronary heart 
disease (CHD) was present in 41% of patients, previous stroke in 13%, type 2 diabetes mellitus 
(T2DM) in 36%, chronic obstructive pulmonary disease (COPD) in 35%, peripheral arterial disease 
(PAD) in 7%, dyslipidemia in 29% and chronic kidney disease in 16%. A history of paroxysmal AF 
(PAF) was present in 17% of patients, while 12% were affected by chronic (persistent or permanent) 
AF (CAF). 
No significant differences in age, gender, BMI, smoking habit, hypertension, dyslipidemia, 
history of CHD, HF, history of stroke, chronic kidney disease, PAD, PAF, and CAF were found 
between CAP and controls (n=150); conversely, CAP patients were more frequently affected by 
COPD and treated with heparins while controls were more frequently treated with oral 
anticoagulants (tab.1). 
Compared to controls, CAP patients showed higher levels of urinary 11-dehydro-TxB2 (110 [69-
151] vs. 163 [130-225] pg/mg creatinine; p<0.001).   
During the in-hospital stay, 31 patients experienced MI (10.3%), most of them were NSTEMI 
(n=29), while 2 were STEMI. Most of the MI occurred within the first days from hospitalization: 52% 
within the first day, 81% within 2 days and 94% within 4 days. 
CAP patients who experienced MI during hospitalization had higher levels of urinary 11-
dehydro-TxB2 than patients who did not (175 [150-271] vs. 163 [130-222] pg/mg creatinine; 
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p=0.042). A COX regression analysis showed that urinary 11-dehydro-TxB2 and PSI score 
independently predicted MI occurrence during the in-hospital stay, after adjusting for possible 
confounding factors (Table 2). 
 
3.2 Corticosteroids and urinary 11-dehydro-TxB2. 
One-hundred and one CAP patients (33%) were treated with i.v. corticosteroids during the first 
day from hospitalization.    
The most common glucocorticoids used were methylprednisolone (n=56; 20-80 mg/day); 
followed by betamethasone (n=28; 4-8 mg/day) and prednisone (n=15; 25-50 mg/day). 
Overall, urinary 11-dehydro-TxB2 was lower in CAP patients treated with glucocorticoids 
compared to untreated ones (147 [120-201] vs. 176 [143-250] pg/mg creatinine; p<0.001)  
Urinary 11-dehydro-TxB2 was also lower in patients treated with glucocorticoids and aspirin 
(100 mg/day) compared to patients treated with aspirin alone (125 [115-140] vs. 140 [130-162] 
pg/mg creatinine; p<0.001). During the in-hospital stay, MI was detected in 7 (6.9%) glucocorticoid-
treated patients and in 24 (12.1%) untreated ones. 
HPLC analyses in randomly selected serum of 63 out of 101 CAP patients treated with 
glucocorticoids showed that serum betamethasone (n=21) and methylprednisolone (n=42) levels 
were 527±366 ng/ml and 348±302 ng/ml, respectively. In 23 randomly selected out of 199 patients 
untreated with glucocorticoids serum levels were undetectable (not shown). 
 
3.3 In vitro study 
3.3.1 Glucocorticoids and agonist-induced platelet aggregation. 
Platelets from HS (n=5, males 3, females 2, age 40.23.4 years) were incubated with ADP (10 
µM) or collagen (2 µg/ml) in presence or absence of scalar concentrations of betamethasone or 
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methylprednisolone (150-600 ng/ml), which corresponded to the levels detected in serum of 
patients upon glucocorticoid administration.  Betamethasone- and methylprednisolone-treated 
platelets showed a dose-dependent decrease of ADP-induced platelet aggregation compared to 
untreated ones (Fig. 1, panels A-D). Conversely, no changes of platelet aggregation were observed 
in betamethasone and methylprednisolone-treated platelets after stimulation with collagen (Fig. 1, 
panels E and F).  
 
3.3.2 Glucocorticoids and TxB2-mediated positive feedback signaling 
Betamethasone-treated platelets stimulated with ADP showed a dose-dependent decrease of 
TxB2 production compared to untreated ones (Fig. 2, panel A). Similar results were observed with 
methylprednisolone -treated platelets stimulated with ADP (Fig. 2, panel B).  
To further investigate the mechanism accounting for glucocorticoid-dependent platelet 
inhibition, we studied cPLA2 phosphorylation, a key enzyme for the release of eicosanoids from the 
platelet membrane that has already been shown to be inhibited by glucocorticoids in other cell types 
[32, 33]. Indeed, betamethasone (Fig. 3, panels A and B) and methylprednisolone dose-dependently 
(Fig. 3, panels C and D) reduced ADP-induced cPLA2 phosphorylation (Fig. 3, panels A and D). 
Furthermore, we found that both betamethasone and methylprednisolone-treated platelets 
stimulated with ADP reduced AA release from platelet membrane compared to control (Fig. 3, 
panels E and F). 
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4. DISCUSSION 
The present study shows that in vivo platelet activation, as assessed by urinary excretion of 11-
dehydro-TxB2, is enhanced and associated with MI in CAP patients, thus reinforcing the hypothesis 
that platelet activation might play a role in precipitating acute coronary syndrome in this setting. 
We also show that glucocorticoids exert an antiplatelet activity via cPLA2 inhibition, an effect that 
may become useful in CAP patients, in whom inflammation and platelet activation coexist. 
Previous studies have outlined the importance of an early recognition of CVEs occurring in the 
acute phase of CAP, as CVEs increase the risk of uneventful outcomes in short- and long-term follow-
up [2, 3]. Among cardiovascular events, MI might occur in approximately 10% of individuals, which 
agrees with the data of the present cohort [2, 34]; consistent with our previous data, most MI were 
NSTEMI while the rate of STEMI was negligible [4]. The present study supports and extends a 
previous report which suggested that platelet activation may be a potential mechanism leading to 
MI in CAP [4, 35]. In accordance with this, we found that urinary excretion of 11-dehydroTxB2 was 
elevated in CAP and associated with MI, suggesting that platelet over-production of this eicosanoid 
could contribute to platelet-related coronary thrombosis and/or coronary dysfunction as a 
consequence of the vasoconstrictor property of TXA2. This last possibility relies on the fact that most 
CAP-related MI were NSTEMI, which may occur because of a mismatch between myocardial oxygen 
“supply and demand” according to the general definition of type 2 MI [26, 36]. However, the 
implication of platelet activation in the pathogenesis of CAP-related MI is still a matter of discussion 
as it is unclear if platelet inhibition results in lowered MI occurrence. Also, preliminary data suggest 
a sort of “aspirin resistance” of CAP patients as platelet TxB2 was not fully inhibited by aspirin [4]. 
Since glucocorticoids can be administered to CAP patients to improve clinical outcomes (despite 
data are still inconsistent [9]) we took advantage of this fact to assess if glucocorticoids also possess 
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antiplatelet activity in vivo. Comparing CAP patients who were given or not given glucocorticoids, 
we found a significant decrease of urinary excretion of 11-dehydro-TxB2 in glucocorticoid-treated 
patients, indicating that these molecules possess an antiplatelet activity. It is also noteworthy to 
point out that the combined administration of glucocorticoids and aspirin rendered lower 11-
dehydro-TxB levels than either of the monotherapies.  
We also investigated if this antiplatelet effect was reproducible in vitro and explored the 
underlying mechanism. Thus, we first measured the circulating levels of glucocorticoids in CAP-
treated patients.  Then we used the range of glucocorticoid concentrations detected in human blood 
to assess the response to agonists of platelets incubated with glucocorticoids. These experiments 
showed that glucocorticoids reduce ADP-induced platelet aggregation coincidentally with an 
impaired production of platelet TxB2. At the same time no effect was seen in collagen-stimulated 
platelets, which is consistent with a previous in vitro study on this topic [12]. We hypothesized that 
the reason why glucocorticoids reduce the aggregation response to weak agonists, e.g. ADP, and 
not to strong agonists, e.g. collagen, is that they interfere with the positive feedback signaling 
mediated by TxA2. For this purpose, we performed further in vitro experiments to see if 
glucocorticoids would lower cPLA2 phosphorylation, which initiates arachidonic acid (AA) 
metabolism via its release from the platelet membrane [37]. Our hypothesis was supported by the 
fact that dose-dependently glucocorticoids reduced cPLA2 phosphorylation and AA release from the 
platelet membrane, suggesting that glucocorticoids could impair platelet activation by down-
regulating AA metabolism.  This mechanism also provides insight into the more powerful reduction 
of urinary 11-dehydro-TxB2 in patients in whom glucocorticoids were combined with aspirin 
compared to patients given aspirin alone. 
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Our data are in line with previous in vitro studies showing that agonist-induced platelet 
aggregation and TxB2 formation were inhibited by prednisolone [11, 12]. We also found an inhibitory 
effect by betamethasone, while previous data regarding other glucocorticoids provided equivocal 
results [11, 12, 38, 39]. Moreover, clinical studies consistently failed to observe an effect on urinary 
TxB2 or platelet aggregation [15-17] though we found an inhibitory effect. Some of these previous 
studies were performed on healthy subjects [15, 16]  in whom the inhibitory effect was difficult to 
appreciate because of normal basal levels of TxB2. Conversely, in patients with high basal levels of 
TxB2, such as those with unstable angina, a very high dosage of glucocorticoids was employed (1 
mg/Kg b.id.)  and could have masked the antiplatelet effect [17]. Experimental studies 
demonstrated that the inhibitory effect of glucocorticoids on platelets is preferentially observed 
with low/ intermediate doses of glucocorticoids [13]. In the present study, glucocorticoids were 
used in patients with basal high values of TxB2 and the glucocorticoid dose was on an average of 0.5 
mg/Kg per day.  
The study has implications and limitations. The results of the present study further contribute 
to the hypothesis that platelet activation might be implicated in CAP-related MI but do not 
establish a cause-effect relationship because trials with antiplatelet drugs are still lacking in this 
setting. The mechanisms accounting for platelet activation in CAP have not been fully elucidated. 
Experimental data demonstrated a virus- or bacteria-dependent platelet interaction which may 
result in platelet activation [40, 41], but it cannot be excluded that systemic inflammation could also 
play a role as suggested by the independent association between PSI and platelet activation [4]. In 
this context, the novel data regarding the antiplatelet activity of glucocorticoids may be useful 
because, in addition to the anti-inflammatory properties, glucocorticoids possess an antiplatelet 
effect. This aspect is of potential interest in a clinical setting where the disease severity is another 
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important factor associated with MI [4]. It is of note that glucocorticoid-treated patients showed 
less incidence of MI compared to untreated ones, but the small sample size limits any conclusion. 
Thus, randomized clinical trials with glucocorticoids are warranted to assess the potential clinical 
usefulness in CAP in reducing the potential cardiovascular events associated to pneumonia.  At 
this regard, the potential usefulness of corticosteroids during CAP was recently supported by a 
meta-analysis, showing that CAP patients treated with glucocorticoids had lower clinical failure 
rates, a shorter hospital stay, and fewer complications [42]. Among the possible adverse events 
investigated (hyperglycemia, neuropsychiatric events, gastrointestinal bleeding and adverse 
cardiac events), only hyperglycemia was significantly more common among corticosteroids-
treated patients, but the harm did not seem to outweigh the benefits.  
In conclusion, we report that platelet TxB2 is overproduced in CAP and may be implicated in MI 
occurrence. Glucocorticoids lower urinary excretion of 11-dehydro-TxB2 and might be a novel tool 
to modulate platelet activation in clinical settings associated with TxA2 over-production. 
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FIGURE LEGENDS 
 
Figure 1. Glucocorticoids and platelet aggregation 
Platelet aggregation was evaluated in PRP incubated with scalar concentrations (150-600 ng/ml) of 
betamethasone (A) or methylprednisolone (C) and stimulated with ADP (10 µM) (A and C) or 
collagen (Coll, 2µg/mL) (E and F) (n=5 experiments) (*p<0.05). 
Representative tracing of platelet aggregation in the presence or not of betamethasone or 
methylprednisolone (150-600 ng/ml) and stimulated with ADP (B and D). 
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Figure 2. Glucocorticoids and platelet TxB2 production 
TxB2 production was evaluated in platelets incubated with scalar concentrations (150-600 ng/ml) of 
betamethasone (A and C) or methylprednisolone (B and D) and stimulated with ADP (10 µM) (A and 
B) or collagen (Coll, 2 µg/mL) (C and D) (n=5 experiments) (*p<0.05). 
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Figure 3. Glucocorticoids and platelet cPLA2 and Arachidonic Acid (AA) production 
cPLA2 phosphorylation was analyzed in platelets incubated with scalar concentrations (150-600 
ng/ml) of betamethasone (panel A) or methylprednisolone (panel C) and stimulated with ADP (10 
µM) (*p<0.05, n=3 experiments). A representative western blot of c-PLA2 phosphorylation in the 
presence or not of betamethasone or methylprednisolone (150-600 ng/ml) (panels B and D). AA 
release in platelets incubated with scalar concentrations (150-600 ng/ml) of betamethasone (E) or 
methylprednisolone (panel F) and stimulated with ADP (10 µM) (E and F) (*p<0.05, n=3 
experiments). 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
27 
 
Tables: 
 
Table 1. Characteristics of CAP patients and controls. 
Variables CAP patients  Control patients p 
 n=300 n=150  
Age (years)* 74.4 ±14.1 73.4±12.2 0.467 
Male sex (%) 66% 69% 0.968 
BMI (kg/m2)* 26.3± 4.4 26.0±4.8 0.476 
Current smokers (%) 23 19 0.418 
Former smokers (%) 37 34 0.602 
Arterial Hypertension  74 77 0.617 
Coronary heart disease (%) 41 36 0.349 
Cerebrovascular disease (%) 13 11 0.644 
Diabetes (%) 36 30 0.275 
Dyslipidemia (%) 29 35 0.233 
Chronic kidney disease (%) 17 19 0.692 
COPD (%) 35 16 <0.001 
Peripheral artery disease (%) 9 11 0.779 
Heart failure (%) 29 26 0.629 
Paroxysmal atrial fibrillation (%) 16 22 0.152 
Chronic atrial fibrillation (%) 14 20 0.161 
PSI* 105.1±35.3 n.a.  
PSI class II (%) 15 n.a.  
PSI class III (%) 22 n.a.  
PSI class IV (%) 40 n.a.  
PSI class V (%) 23 n.a.  
    
ASA (%) 34 32 0.698 
VKA (oral anticoagulants) (%) 17 26 0.042 
Heparins (%) 9 2 0.012 
ACE inhibitors/ARBs (%) 58 60 0.813 
Statins (%) 34 31 0.594 
ACE: angiotensin converting enzyme; ARBs: Angiotensin receptor blockade; ASA: aspirin; CAP: community-
acquired pneumonia; BMI: body mass index; COPD: chronic obstructive pulmonary disease; PSI: pneumonia 
severity index, n.a.: not applicable, VKA: vitamin K antagonists; *Data are expressed as mean±SD 
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Table 2 
Adjusted hazard ratios (HR), based on a Cox Proportional Hazards model, of in-hospital MI 
according to selected variables. 
 
Variables  HR* P  CI 95% 
Lower Upper 
Urinary 11-dehydro-TxB2 1.002 0.005 1.001 1.004 
PSI score 1.015 0.003 1.005 1.025 
After adjusting for sex, BMI, PSI score, smoking habit, history of CHD, stroke, dyslipidemia, T2DM, 
hypertension, HF, renal failure, COPD, PAD, paroxysmal and chronic atrial fibrillation.   
* HR for an increasing unit change in the independent factor 
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